title: Docetaxel in the treatment of children with refractory or relapsed hepatoblastoma.
abstract: We report on the use of single-agent docetaxel (100 mg/m(2) in children >10 kg, 3.3 mg/kg in children <10 kg), given as a 1-hour infusion at 21-day intervals in 5 children with relapsed or refractory hepatoblastoma. One patient achieved complete remission of pulmonary metastases after 2 courses of docetaxel and remains well 10 years later, after completion of 13 courses of docetaxel and whole-lung radiotherapy. One patient showed a partial response to docetaxel based on α-fetoprotein measurements. Docetaxel shows some activity in progressive hepatoblastoma in this small case series and is a potential drug for future study in this disease.
authors.affiliation: Department of Haematology and Oncology, Great Ormond Street Hospital, London, UK. s.gavin@doctors.org.uk
authors.forename: Sally L
authors.initials: SL
authors.lastname: George
authors.forename: Susan
authors.initials: S
authors.lastname: Broster
authors.forename: Julia C
authors.initials: JC
authors.lastname: Chisholm
authors.forename: Penelope
authors.initials: P
authors.lastname: Brock
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D000077143:Docetaxel; D005260:Female; D018197:Hepatoblastoma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel